Nur Nicholson Sells 7,725 Shares of Apellis Pharmaceuticals (NASDAQ:APLS) Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) insider Nur Nicholson sold 7,725 shares of the business’s stock in a transaction dated Thursday, January 22nd. The shares were sold at an average price of $21.77, for a total value of $168,173.25. Following the completion of the sale, the insider owned 71,118 shares in the company, valued at approximately $1,548,238.86. This trade represents a 9.80% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Nur Nicholson also recently made the following trade(s):

• On Tuesday, January 20th, Nur Nicholson sold 2,203 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $19.79, for a total value of $43,597.37.
• On Tuesday, January 13th, Nur Nicholson sold 2,618 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $22.19, for a total value of $58,093.42.

Apellis Pharmaceuticals Trading Down 1.1%

NASDAQ APLS opened at $21.76 on Friday. Apellis Pharmaceuticals, Inc. has a 52 week low of $16.10 and a 52 week high of $30.91. The company has a debt-to-equity ratio of 0.90, a quick ratio of 3.10 and a current ratio of 3.54. The stock’s 50 day moving average price is $23.02 and its two-hundred day moving average price is $23.56. The stock has a market capitalization of $2.75 billion, a price-to-earnings ratio of 70.18 and a beta of 0.31.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings data on Thursday, October 30th. The company reported $1.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.03 by $0.64. Apellis Pharmaceuticals had a net margin of 4.43% and a return on equity of 18.94%. The company had revenue of $458.58 million for the quarter, compared to the consensus estimate of $364.58 million. During the same period last year, the company earned ($0.46) earnings per share. The firm’s revenue was up 133.0% compared to the same quarter last year. As a group, analysts anticipate that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Apellis Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in APLS. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Apellis Pharmaceuticals by 207.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,559 shares of the company’s stock valued at $667,000 after purchasing an additional 19,944 shares during the last quarter. Goldman Sachs Group Inc. raised its position in shares of Apellis Pharmaceuticals by 26.6% in the first quarter. Goldman Sachs Group Inc. now owns 307,709 shares of the company’s stock valued at $6,730,000 after purchasing an additional 64,742 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Apellis Pharmaceuticals by 4.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 222,634 shares of the company’s stock worth $4,869,000 after buying an additional 9,747 shares during the last quarter. Focus Partners Wealth boosted its holdings in shares of Apellis Pharmaceuticals by 118.4% during the 1st quarter. Focus Partners Wealth now owns 21,883 shares of the company’s stock worth $479,000 after buying an additional 11,862 shares during the period. Finally, Acadian Asset Management LLC boosted its holdings in shares of Apellis Pharmaceuticals by 1,146.2% during the 1st quarter. Acadian Asset Management LLC now owns 23,976 shares of the company’s stock worth $522,000 after buying an additional 22,052 shares during the period. Institutional investors own 96.29% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently weighed in on APLS. Bank of America upgraded Apellis Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $28.00 price objective for the company in a report on Wednesday. TD Cowen reduced their price target on Apellis Pharmaceuticals from $50.00 to $45.00 and set a “buy” rating for the company in a research report on Friday, October 31st. Robert W. Baird raised their price target on Apellis Pharmaceuticals from $50.00 to $52.00 and gave the company an “outperform” rating in a research note on Friday, October 31st. Needham & Company LLC lowered their price target on Apellis Pharmaceuticals from $29.00 to $28.00 and set a “buy” rating on the stock in a research report on Tuesday, January 13th. Finally, Wells Fargo & Company cut their price objective on Apellis Pharmaceuticals from $29.00 to $26.00 and set an “overweight” rating for the company in a report on Tuesday, January 20th. Twelve analysts have rated the stock with a Buy rating, six have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $33.53.

More Apellis Pharmaceuticals News

Here are the key news stories impacting Apellis Pharmaceuticals this week:

• Positive Sentiment: BofA upgraded APLS to Buy and cited a stronger-than-expected launch trajectory for Apellis’s newly approved kidney-disease therapy, assigning a $28 price target — a vote of confidence that implies material upside if commercial momentum continues. Apellis Raised to Buy at Bank of America
• Positive Sentiment: An analyst note highlights early uptake of Empaveli and argues current valuation understates its revenue potential; continued strong launch metrics could drive a re‑rating and support upside from current levels. Apellis Valuation Ignores Empaveli Potential, Says Analyst
• Neutral Sentiment: Wells Fargo trimmed its price target (from $29 to $26) but kept an Overweight rating — a mixed signal that reduces upside expectations while leaving institutional support intact. Wells Fargo lowers price target on Apellis
• Neutral Sentiment: RBC Capital reiterated a Hold rating, a neutral stance that may temper buying interest from investors seeking stronger analyst conviction. RBC Capital Sticks to Its Hold Rating for Apellis Pharmaceuticals (APLS)
• Negative Sentiment: Multiple senior insiders — including CEO Cedric Francois, CFO Timothy Sullivan, General Counsel David Watson and others — filed Form 4 sales on Jan. 20–22 (large, clustered disposals totaling many tens of thousands of shares). Even if routine (diversification or option-related), clustered executive selling typically weighs on near‑term sentiment and likely contributed to the stock decline. See CEO filing for details. CEO Cedric Francois Form 4

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.